The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Per CNBC, Eli Lilly has acquired the psychedelic drug maker AtaiBeckley. This deal extends Big Pharma's broader embrace of psychedelics as treatments for mental health conditions, a class of drugs long considered stigmatized.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton